Watch More Highlights

Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses a currently enrolling phase III trial on a new strategy to decrease exposure time to ibrutinib, which has the potential to change the standard of care for patients 70 years or older with previously untreated chronic lymphocytic leukemia (Abstract 1751).

Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.